ZFIN ID: ZDB-FISH-200227-8
Fish name: cnr2upr1/upr1(NHGRI-1)
Genotype: cnr2upr1/upr1 (NHGRI-1)
Targeting Reagent: none
HUMAN DISEASE MODELED by cnr2upr1/upr1(NHGRI-1)
Human Disease Conditions Citations
anxiety disorder standard conditions Acevedo-Canabal et al., 2019
GENE EXPRESSION
Gene expression in cnr2upr1/upr1(NHGRI-1)
RNA expression No data available
Protein expression No data available
Reporter gene expression No data available
PHENOTYPE
Phenotype in cnr2upr1/upr1(NHGRI-1)
Phenotype Conditions Figures
locomotory exploration behavior decreased occurrence, abnormal standard conditions Fig. 2Fig. 3Fig. 5 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, abnormal chemical treatment: HU-308 Fig. 5 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, abnormal chemical treatment: JWH-133 Fig. 5 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, exacerbated chemical treatment: valproic acid Fig. 3 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, exacerbated chemical treatment: pentetrazol Fig. 4 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, abnormal chemical treatment: JWH-133 Fig. 5 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, abnormal chemical treatment: HU-308 Fig. 5 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, abnormal chemical treatment: [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-3-indolyl]-(4-methoxyphenyl)methanone Fig. 5 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, abnormal standard conditions Fig. 2Fig. 3Fig. 5 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, ameliorated chemical treatment: valproic acid Fig. 3 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal chemical treatment: SR 144528 Fig. 5 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal chemical treatment: JWH-133 Fig. 5 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal chemical treatment: valproic acid Fig. 3 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal chemical treatment: HU-308 Fig. 5 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal standard conditions Fig. 2Fig. 3Fig. 4Fig. 5 from Acevedo-Canabal et al., 2019
response to light stimulus increased occurrence, exacerbated chemical treatment: pentetrazol Fig. 4 from Acevedo-Canabal et al., 2019
swimming behavior increased occurrence, exacerbated chemical treatment: pentetrazol Fig. 4 from Acevedo-Canabal et al., 2019
swimming behavior occurrence, abnormal standard conditions Fig. 2 from Acevedo-Canabal et al., 2019

CITATIONS  (1)